Cautionary Note Regarding Forward-looking Statements

• This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

• You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.

• Risks and uncertainties for Melinta Therapeutics, Inc. (the “Company”) are more fully described in the Company’s filings with the SEC, including in its most recently filed Annual Report on Form 10-K, its most recently filed Quarterly Report on Form 10-Q and its Current Reports on Form 8-K.
Who is Melinta Therapeutics?

- Antibiotics-focused company, recently listed on Nasdaq (MLNT)
- Four US FDA approved antibiotics
- Fully-established & highly leverageable operating infrastructure
- Well-experienced, ID-focused leadership team
- Deep, sustainable pipeline of early- to late-stage assets
- Strong market exclusivity period afforded by GAIN Act and IP
- **Well capitalized to support strong future growth**

Leading Pure-play Antibiotics Company
## A New Model for Success in Antibiotics

<table>
<thead>
<tr>
<th>Company</th>
<th>Multiple Approved Products</th>
<th>Gram-negative Pipeline</th>
<th>Successful Phase 3 Program</th>
<th>Multiple Late-stage Indications</th>
<th>Sustainable Discovery Capabilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melinta (MLNT)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Achaogen (AKAO)</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paratek (PRTK)</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetraphase (TTPH)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nabriva (NBRV)</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Company estimates
Robust and Complementary Product Portfolio of Four Approved Assets with Significant Commercial Potential

<table>
<thead>
<tr>
<th>Baxdela™ (delafloxacin)</th>
<th>VABOMERE™ meropenem and vaborbactam for injection (4 g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSSSI Patients with Comorbidities in the Hospital, Emergency and Outpatient Setting</td>
<td>cUTI including those caused by KPC-mediated CRE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Orbactiv® (oritavancin)</th>
<th>Minocin® (minocycline) for injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gram (+) ABSSSI in the Emergency and Outpatient Setting</td>
<td>Acinetobacter in the Hospital Setting</td>
</tr>
</tbody>
</table>

Unique Market Value for Each Approved Product Optimized By Company Infrastructure and Commitment to Antibiotics
### Industry Leading Portfolio and Pipeline

<table>
<thead>
<tr>
<th>PRODUCT/INDICATION</th>
<th>PRE CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>NDA Submitted</th>
<th>FDA Approved</th>
<th>EMA Submitted</th>
<th>EMA Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baxdela</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vabomere</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complicated Urinary Tract Infections (cUTI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Orbactiv</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABSSSI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Minocin IV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious infections due to select organisms including \textit{Acinetobacter}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Baxdela</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community-acquired Bacterial Pneumonia (CABP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Radezolid</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ESKAPE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“Superbugs”</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Other Non-Core Assets**

<table>
<thead>
<tr>
<th>PRODUCT/INDICATION</th>
<th>PRE CLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>NDA Submitted</th>
<th>FDA Approved</th>
<th>EMA Submitted</th>
<th>EMA Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fusidic Acid</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABSSSI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Solithromycin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Baxdela**: Development ongoing in Japan through partner. Potential for other indications.
- **Fusidic Acid**: One positive phase III complete.
- **Solithromycin**: Development ongoing in Japan through partner. Potential for other indications.
Successful Out-licensing Offers Potential to Expand Partnerships Across Full Portfolio of Assets

Active process underway to license global rights to products acquired from The Medicines Company
Melinta’s 2018 Corporate Objectives

1. Maximizing Product Portfolio

2. Financial & Operational Strength

3. Advancing New Drug Portfolio
Q1 and YTD Business Highlights

Maximizing Product Portfolio

- $14.8 million of net revenue* in Q1
  - $11.8 million of net product sales in Q1
- Launched Melinta Antimicrobial Stewardship Program at MAD-ID
- Strong presence at all major ID-related medical meetings with ~20 posters at upcoming ASM-Microbe meeting

Financial & Operational Strength

- Integration of The Medicines Company ID Business complete
  - Sales force cross training complete – new incentive plan in place
  - Cost synergies to be achieved
  - Sales force expanded to maximize company portfolio of products
- Actively evaluating BD opportunities to monetize valued portfolio ex-US

Advancing New Drug Portfolio

- Baxdela CABP trial enrollment on target
- Vabomere EU application on target
- CARB-X funding received to support advancement of new antibiotic class
- Strong ECCMID presence with 12 posters & presentations
- Submissions of delafloxacin ongoing in Europe and Latin America

Fully capitalized with recent offering to support current growth plans of the company

* Excludes $2.7 million BARDA grant funding included in Other Income
Vabomere™: Launch Momentum Continues

- 97 formulary approvals to-date
- 99% Formulary Approval

• ~200 unique accounts ordering
• 52% of accounts reordering

Cumulative Ordering Accounts

Source: Company data
Baxdela™: Off to a Terrific Start

- 177 million patient lives have access
- 90 formulary approvals to-date
- 12 different specialties prescribing
- >30 additional formulary meetings scheduled

Week-over-week Prescribing Nearly Doubled Over Last 8 Weeks

Source: Company data
Orbactiv®: Accelerating Growth Quarter-on-quarter

- Average of 48 new accounts per month*
- 70% of volume purchased by the hospital
- >50% demand over Q1 2017

# of Accounts Ordering

- >30% Quarter-on-quarter Growth

# of New Accounts Ordering

- 5 or More Boxes/Quarter
- ~40% Quarter-on-quarter Growth

*Over last 6 months

Source: Company data
Minocin® IV: Sales Reinvigorated with Vabomere

- Double-digit growth vs. Q1 2017 on a pro forma basis
- Increased level of product growth YTD correlation with launch of Vabomere

Source: Company data
Commercial Efficiency and Optimization Underway
Expands Share of Voice for All Products by 2-3x to ~170 Current

Step 1: Launch
- Incentive Plan 1
  - Baxdela® (delafloxacin)
    for injection
- Incentive Plan 2
  - VABOMERE™ meropenem and vaborbactam
    for injection (4 g)
  - Orbactiv® (oritavancin)
    for injection
  - Minocin® (minocycline)
    for injection

Step 2: Optimize
- New Incentive Plan
  - Baxdela® (delafloxacin)
  - VABOMERE™ meropenem and vaborbactam
    for injection (4 g)
  - Orbactiv® (oritavancin)
    for injection
  - Minocin® (minocycline)
    for injection
Melinta is Now Powered by CARB-X

- Agreement supporting development of new antibiotic class (the pyrrolocytosine class for ESKAPE pathogens)

- Melinta will receive initial grant of up to $2.3 million with potential to receive additional $3.9 million to support existing discovery efforts

- Initial goal of selecting lead candidate & completing IND-enabling program
Strategy for Long-term Growth and Expansion

**DRIVE**

- Sales of >$1 billion from four US-approved antibiotics

**DEVELOP**

- Additional indications during 10+ years of market exclusivity for key assets afforded by GAIN Act

**DISCOVER**

- Completely novel anti-infectives leveraging our proprietary, Nobel Prize-winning discovery platform

**EXPAND**

- Ex-US partnerships across entire product portfolio to enhance company value

Continue to Execute Growth-accelerating Business Development Activities
2018 Key Catalysts

Maximizing Product Portfolio
- Launch updates for Baxdela and Vabomere
- Country filings/approvals in South & Central America for delafloxacin
- Ex-US partnerships for balance of portfolio
- Baxdela Phase 3 CABP study enrollment completion

Financial & Operational Strength
- Potential cost synergies and lower operating expenses
- Roll out of Melinta Antimicrobial Stewardship Program
- Business development opportunities

Advancing New Drug Portfolio
- EMA regulatory approval for Vabomere
- TANGO-2 additional data and potential publications
- Progress on ESKAPE program
- Focused publication strategy; 30+ planned

When Strategy is Clear, EXECUTION Becomes the Strategy
# Q1 2018 Financial Highlights – Strong Start to 2018

<table>
<thead>
<tr>
<th>Metrics (in millions)</th>
<th>GAAP</th>
<th>Adjustment</th>
<th>Non-GAAP</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Net Revenue</td>
<td>$14.8</td>
<td></td>
<td>$14.8</td>
<td>Excludes BARDA grant funding</td>
</tr>
<tr>
<td>- Product</td>
<td>11.8</td>
<td></td>
<td>11.8</td>
<td></td>
</tr>
<tr>
<td>- Contract</td>
<td>3.0</td>
<td></td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>COGS</td>
<td>7.7</td>
<td>(4.7)</td>
<td>3.0</td>
<td>Deal-related amortization</td>
</tr>
<tr>
<td>Total Operating Expenses</td>
<td>$50.8</td>
<td>(4.6)</td>
<td>$46.1</td>
<td></td>
</tr>
<tr>
<td>- R&amp;D</td>
<td>16.1</td>
<td>(0.3)</td>
<td>15.8</td>
<td>Stock comp</td>
</tr>
<tr>
<td>- SG&amp;A</td>
<td>34.6</td>
<td>(4.3)</td>
<td>30.3</td>
<td>Stock comp, M&amp;A-related</td>
</tr>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$91.5</td>
<td></td>
<td>$91.5</td>
<td>Approximately ~$165 post financing</td>
</tr>
<tr>
<td>Long-term Debt</td>
<td>$147.8</td>
<td></td>
<td>$147.8</td>
<td></td>
</tr>
<tr>
<td>Common Shares Outstanding</td>
<td>31.4</td>
<td></td>
<td>31.4</td>
<td>Post financing: 56.0</td>
</tr>
<tr>
<td>Options, RSUs and Warrants Outstanding</td>
<td>6.1</td>
<td></td>
<td>6.1</td>
<td>Current: 7.6</td>
</tr>
</tbody>
</table>

Anticipate Orbactiv and Minocin to Achieve Net Sales of $36-40 Million for FY 2018
Melinta Therapeutics, The Antibiotics Company

Four approved antibiotic assets with >$1 billion sales potential

Robust drug development pipeline to fuel future growth

Global footprint* with significant expansion potential

Strong combined talent, processes and capabilities

Fully capitalized to execute strategy for growth

Nobel Prize-winning technology

Proprietary discovery expertise to address emerging resistance

* Including partnership agreements
APPENDIX
Creating the Pure Play Antibiotics Leader

- **FDA approval**
  - **Jun 2017**

- **NASDAQ: MLNT**
  - **Nov 2017**

- **Melinta acquires The Medicines Company (ID Business)**
  - **Jan 2018**

**Transformed into Largest Pure-play Antibiotics Company**
Vabomere: Fixed Dose, IV Monotherapy Targeting KPC-producing, Carbapenem-resistant Enterobacteriaceae

Indications:
• cUTI (approved)
• Acute pyelonephritis (approved)

Attributes / Differentiation:
• Product for serious Gram-negative pathogens, an area of significant need
• Fixed dose, no requirement for plasma monitoring
• Meropenem “backbone” with safety profile similar to meropenem alone
• Conducted first & only supportive study as monotherapy in CRE infections versus a range of “best available therapy” regimens

- $990/day WAC
- 2g meropenem / 2g vaborbactam
- TID dosing
- Fixed dose
Baxdela: Fixed Dose, IV/Oral Monotherapy Targeting Serious Mixed Pathogen Infections

Indications:
• ABSSSI (approved)
• CABP (single Phase 3, >75% enrolled)

Attributes / Differentiation:
• Gram-positive, Gram-negative, MRSA (only approved FQ with coverage)
• Interchangeable IV and Oral administration
• Fixed dose, no food effect, no drug interactions (other than antacids)
• <1% discontinuation due to treatment-related AEs in ABSSSI Phase 3s
• Large database of co-morbid patients studied

$135/day WAC
• 450mg tablet
• BID dosing
• Fixed dose

$265/day WAC
• 300mg vial
• BID dosing
• Fixed dose
Orbactiv & Minocin Strategy
Demonstrating Consistent Growth Since Launch

1. Drive Value from Reinvigorated Salesforce
2. Leverage Power of 100% Dedicated Anti-infectives Business
3. Focus on Newly Accessible Opportunities, e.g. Outpatient Clinics Surrounding Hospitals

$34 Million FY 2017 Sales
Attractive Product Portfolio for Multiple Sites of Care

Hospital Avoidance

Hospital Transition of Care (Post-Discharge)

Specialty Community

- Baxdela® (delafloxacin) for injection
- Orbactiv® (oritavancin) for injection
- Minocin® (minocycline) for injection
- Vabomere™ (meropenem and vaborbacam for injection [4 g])

- High Value PCP
- Urgent Care
- LTC